Scienza e Tecnologia
Waters New Bioseparations Tools Accelerate and Improve Development of RNA-based Vaccines and Therapies Using LC-MS Analysis
Large molecule RNA (ribonucleic acid) therapeutics represent some of the most exciting and potentially life-saving developments in pharmaceuticals today. They include new and more effective vaccines for diseases like COVID-19, personalized cancer treatments, as well as emerging CRISPR RNA therapies that address challenging genetic conditions, such as sickle cell anemia.
"As RNA-based therapies are prepared for widespread use, more direct composition measurements are needed to ensure stability, safety, and effectiveness for patients," said Erin Chambers , Vice President, Consumables and Lab Automation at Waters Corporation. "The combination of Waters enzymes, reagents, and software are specially designed to simplify the confirmation of sequence and modifications of complex molecules. These analytical tools can accelerate RNA therapeutic development and lower barriers for use by LC-MS non-experts."
"As innovators looking to help our customers advance nucleic acid-based therapies and reduce the burden of serious diseases, we are always seeking new technologies to improve characterization and accelerate development," said Arnaud Delobel , PhD, R&D and Innovation Director at Quality Assistance S.A. and beta tester of the Waters RNA analytical tools. "Waters new enzymes efficiently digest mRNA and sgRNA with short incubation times and data processing in MAP Sequence allows the user to obtain reproducible results quickly with confidence."
The Waters RNA analytical tools include:
Used together within a workflow, the tools generate an LC-MS fingerprint to confirm product identity, purity, and efficacy. The tools improve sequence coverage, LC-MS spectral data quality, and data interpretation. Supported by the compliance-ready waters_connect software platform, these tools help transition LC and LC-MS-based digestion analysis from discovery and development to release and at-line process analytical testing.
Waters RapiZyme RNAses and IonHance HFIP are now available. The new MAP Sequence App on waters_connect software will be available on October 18, 2024 .
( www.waters.com )
Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,500 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Contact:
Janice Foley
Senior Public Relations Manager, Corporate Communications
Waters Corporation
janice_foley@waters.com
+1.617.823.5555
100% RNA sequence coverage achieved for HPRT sgRNA digested with RapiZyme MC1 and RapiZyme Cusativin compared to traditional digestion methods such as RNase T1. Waters Application Note 720008539EN: "Tunable Digestions of RNA Using RapiZyme RNases to Confirm Sequence and Map Modifications" .
IonHance HFIP reagents are certified to contain less than 100 ppb sodium and less than 100 ppb potassium content, resulting in reduced adduct formation and improved sensitivity of RNA detection compared to commercially available HFIP. Waters Application Note 720008540EN: "Evaluating IonHance Hexafluoroisopropanol (HFIP) for Enhanced LC-MS Oligonucleotide Analysis"
��Waters RapiZyme RNase protocol simplifies sample preparation with three steps including reagent preparation, RNA digestion, and heat inactivation without the need to add chemical denaturants and enzyme inhibitors.
View original content: https://www.prnewswire.co.uk/news-releases/waters-new-bioseparations-tools-accelerate-and-improve-development-of-rna-based-vaccines-and-therapies-using-lc-ms-analysis-302272407.html